Compare Nucor Corporation (NUE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Viatris Inc — how do they compare? Nucor Corporation trades at $230.8 (market cap $52.55B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Nucor Corporation is far larger — about 2.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| NUE | VTRS | |
|---|---|---|
Market Cap | $52.55B | $19.79B |
Sector | Basic Materials | Health |
52-Week High | $266.35 | $17.39 |
52-Week Low | $131.78 | $8.74 |
Enterprise Value | $57.19B | $32.00B |
Dividend Yield | 0.97% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $233.2, down 1.44% over 24 hours, with technical indicators showing a bearish trend near key support at $228. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has stabilized around $32.5B in 2025 after declines from 2022 peaks, while net margins compressed to 5.36%. Analyst sentiment remains positive with a 62.5% buy rating and $263.11 consensus target, supported by strong cash flow and a 53-year dividend growth streak.
NUE offers value with reasonable valuation multiples (P/E 22.89, P/S 1.55) and robust shareholder returns, but faces risks from steel demand volatility and margin pressure. The upcoming Q2 earnings report on July 27, 2026, will be critical for confirming growth trajectory amid economic uncertainties.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
